Vanguard Group Inc Galera Therapeutics, Inc. Transaction History

Vanguard Group Inc

  • $4.96 Trillion
  • Q1 2024

A detailed history of Vanguard Group Inc transactions in Galera Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 448,330 shares of GRTX stock, worth $98,632. This represents 0.0% of its overall portfolio holdings.

Number of Shares
448,330
Previous 448,330 -0.0%
Holding current value
$98,632
Previous $62,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$0.09 - $0.27 $54,769 - $164,307
-608,547 Reduced 57.58%
448,330 $62,000
Q3 2023

Nov 14, 2023
SELL
$0.17 - $3.0 $63,258 - $1.12 Million
-372,109 Reduced 26.04%
1,056,877 $190,000
Q2 2023

Aug 14, 2023
BUY
$2.5 - $3.42 $906,517 - $1.24 Million
362,607 Added 34.0%
1,428,986 $4.46 Million
Q1 2023

May 15, 2023
BUY
$1.48 - $2.68 $809,777 - $1.47 Million
547,147 Added 105.38%
1,066,379 $2.73 Million
Q4 2022

Feb 10, 2023
BUY
$1.34 - $1.76 $114,216 - $150,015
85,236 Added 19.64%
519,232 $773,000
Q3 2022

Nov 14, 2022
SELL
$1.15 - $2.1 $2,274 - $4,153
-1,978 Reduced 0.45%
433,996 $755,000
Q2 2022

Aug 12, 2022
SELL
$1.24 - $2.39 $1,747 - $3,367
-1,409 Reduced 0.32%
435,974 $567,000
Q1 2022

May 13, 2022
SELL
$2.01 - $4.19 $63,347 - $132,052
-31,516 Reduced 6.72%
437,383 $1.04 Million
Q4 2021

Feb 14, 2022
SELL
$1.27 - $8.28 $16,033 - $104,534
-12,625 Reduced 2.62%
468,899 $2.15 Million
Q2 2021

Aug 13, 2021
BUY
$6.08 - $10.44 $2.93 Million - $5.03 Million
481,524 New
481,524 $4.73 Million

Others Institutions Holding GRTX

# of Institutions
38
Shares Held
10.7M
Call Options Held
10.3K
Put Options Held
0
View Full List

About Galera Therapeutics, Inc.

GRTX Quotes by TradingView
  • Ticker GRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,821,600
  • Market Cap $5.9M
  • Description
  • Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...
More about GRTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email